eRapa is a company that Biodexa Pharmaceuticals PLC recently acquired for the treatment of familial adenomatous polyposis (FAP), an inherited condition which increases the risk of developing colon cancer. The acquisition of eRapa is considered transformational for Biodexa Pharmaceuticals PLC, as it holds promising phase 2 data showing positive results in reducing polyp burden and non-progression rates in FAP patients.